Your session is about to expire
← Back to Search
Etripamil NS for Supraventricular Tachycardia
Study Summary
This trial is testing a new drug, etripamil NS, to see if it is safe for people with PSVT. Patients will be given a system to help document their symptoms and will take the drug themselves if necessary. After an episode, they will come back to the site and may continue in the trial.
- Supraventricular Tachycardia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the margin of error for Etripamil NS?
"Etripamil NS is safe according to our 3-point scale at Power. This medication has progressed to Phase 3 clinical trials, which signifies that there is some data supporting efficacy as well as multiple rounds of data affirming safety."
Are there any other precedents for using Etripamil NS in a medical setting?
"The first clinical trials for Etripamil NS were completed in 2018 at CHU de Lille - Institut Cœur Poumon. As of now, a total of 2 studies have been conducted with 4 more ongoing. The majority of these active studies are being performed in Lévis, Quebec.""
Are there still vacancies in this clinical trial for potential volunteers?
"The most recent information available on clinicaltrials.gov suggests that this trial is still enrolling patients. The posting date was September 2nd, 2019 and the last update was on October 13th, 2022."
Is this an innovative study?
"Since 2018, there have been 4 clinical trials involving Etripamil NS. The first study was sponsored by Medpace, Inc and took place in 2018 with 701 participants. After the Phase 3 drug approval in 2018, subsequent studies of Etripamil NS occurred across 180 cities and 21 countries."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger